Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Wuxi Biologics Cayman Inc ADR (OP: WXXWY ) 3.600 -0.020 (-0.55%) Streaming Delayed Price Updated: 3:57 PM EDT, Mar 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 178,024 Open 3.700 Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 3.620 Today's Range 3.590 - 3.700 52wk Range 3.590 - 13.84 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Congressional Scrutiny Intensifies On Chinese Biotech Firms: WuXi AppTec Faces Biotech Exodus March 14, 2024 Amidst regulatory challenges, WuXi AppTec faces backlash from industry giants. Biotechnology Innovation Organization cuts ties, citing national security concerns. Shares plummet as U.S. bills target... Via Benzinga Week In Review: BeiGene Signs $1.3 Billion Deal For Preclinical CDK2 Inhibitor From Boston’s Ensem November 25, 2023 Beijing’s BeiGene acquired global rights to a preclinical novel cyclin-dependent kinase 2 (CDK2) inhibitor from Boston’s Ensem Therapeutics in a $1.3 billion agreement. Ensem will receive an upfront... Via Talk Markets Performance YTD -50.48% -50.48% 1 Month -17.24% -17.24% 3 Month -51.15% -51.15% 6 Month -67.54% -67.54% 1 Year -69.15% -69.15% More News Read More Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal November 18, 2023 Via Talk Markets Week In Review: Eccogen Out-Licenses GLP-1 Agonist To AstraZeneca In $2 Billion Deal November 11, 2023 Via Talk Markets Week In Review: BeiGene Options DualityBio ADC In $1.3 Billion Agreement July 15, 2023 Via Talk Markets Strong Consumer Turnout Drives Hong Kong Stocks Higher Friday As China's Former Premier Li Keqiang Dies At 68 October 27, 2023 Via Benzinga Week In Review: China's Biopharmas Announce $2.5 Billion In Deals October 21, 2023 Via Talk Markets Week In Review: QYuns Plans Hong Kong IPO For Autoimmune/Allergic Disease Portfolio October 07, 2023 Via Talk Markets Topics Initial Public Offering Exposures Securities Market Week In Review: WuXi Biologics Out-Licenses Four TCE Antibodies To GSK In $1.5 Billion Pact January 07, 2023 Via Talk Markets Week In Review: Ten Biggest 2022 China Biopharma Deals Worth $21.5 Billion December 31, 2022 Via Talk Markets Wuxi Biologics Will Be Removed From U.S. Commerce Department's ‘Unverified List’ October 09, 2022 Via Talk Markets Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.